What to Know for the 2022-2023 Flu Season

According to the Centers for Disease Control and Prevention (CDC), there were as many as 14,000 flu-related deaths and...

Read More

Is it Worth the Download: Digital Therapeutics' Place in Healthcare

Digital therapeutics (DTx) uses software programs to prevent, manage or treat diseases. They may be used with or...

Read More

Biosimilars Versus Interchangeability: What You Need to Know

Specialty medications continue to be a large source of drug spend, in particular biologic drugs. Biosimilars pose an...

Read More

Demonstrating the Value of Specialty Medications that Treat Cystic Fibrosis

Cystic fibrosis (CF) is a rare genetic disorder that affects one in 3,900 live births. There are approximately 30,000...

Read More

Insights for Remaining Audit Ready: CMS Releases 2021 Audit Enforcement Report

On June 7, 2022, the Centers for Medicare and Medicaid Services (CMS) released the 2021 Part C and Part D Program Audit...

Read More

Elixir Launches Specialty Generic Enhancement that Leads to Thousands in Annual Savings for Plan...

Elixir announced the launch of a specialty generic medication enhancement to our suite of solutions effective June 1,...

Read More

The Last Step in Specialty Drug Management: Individualized Care

With the growing specialty drug pipeline that is contributing to nearly half of overall drug spend, we have been...

Read More

Blending Business Strategies and Clinical Expertise Can Help Manage Rising Drug Spend

The role of the Clinical Account Executive (CAE) at Elixir is a very important one for helping clients identify...

Read More

Demonstrating the Value of Specialty Medications that Treat Various Cancers

Approximately 40% of Americans will be diagnosed with some type of cancer in their lifetime. Many cancer treatments...

Read More

Medicare Marketing Modifications: The Old and the New

This February, Centers for Medicare and Medicaid Services (CMS) announced an update to the Medicare Communications and...

Read More